A detailed history of Amalgamated Bank transactions in Erasca, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 2,251 shares of ERAS stock, worth $4,389. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,251
Previous 2,251 -0.0%
Holding current value
$4,389
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$1.67 - $2.55 $7,052 - $10,768
-4,223 Reduced 65.23%
2,251 $5,000
Q4 2023

Feb 06, 2024

SELL
$1.67 - $2.49 $1,118 - $1,668
-670 Reduced 9.38%
6,474 $14,000
Q1 2023

May 02, 2023

SELL
$2.74 - $4.44 $2,931 - $4,750
-1,070 Reduced 13.03%
7,144 $22,000
Q2 2022

Aug 15, 2022

BUY
$4.58 - $8.72 $3,540 - $6,740
773 Added 10.39%
8,214 $46,000
Q1 2022

Jun 30, 2022

BUY
$8.6 - $15.48 $63,992 - $115,186
7,441 New
7,441 $64,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $238M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.